- Home
- KROS vs ATRO Comparison
KROS vs ATRO Comparison
Compare KROS & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- ATRO
- Stock Information
- Founded
- KROS 2015
- ATRO 1968
- Country
- KROS United States
- ATRO United States
- Employees
- KROS N/A
- ATRO N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- KROS Health Care
- ATRO Industrials
- Exchange
- KROS Nasdaq
- ATRO Nasdaq
- Market Cap
- KROS 589.8M
- ATRO 592.4M
- IPO Year
- KROS 2020
- ATRO N/A
- Fundamental
- Price
- KROS $10.86
- ATRO $16.91
- Analyst Decision
- KROS Buy
- ATRO Hold
- Analyst Count
- KROS 11
- ATRO 1
- Target Price
- KROS $45.33
- ATRO $17.00
- AVG Volume (30 Days)
- KROS 1.9M
- ATRO 275.9K
- Earning Date
- KROS 02-26-2025
- ATRO 02-26-2025
- Dividend Yield
- KROS N/A
- ATRO N/A
- EPS Growth
- KROS N/A
- ATRO N/A
- EPS
- KROS N/A
- ATRO N/A
- Revenue
- KROS $651,000.00
- ATRO $782,178,000.00
- Revenue This Year
- KROS $303.39
- ATRO $15.70
- Revenue Next Year
- KROS N/A
- ATRO $6.98
- P/E Ratio
- KROS N/A
- ATRO N/A
- Revenue Growth
- KROS 8037.50
- ATRO 19.95
- 52 Week Low
- KROS $9.78
- ATRO $14.13
- 52 Week High
- KROS $73.00
- ATRO $23.74
- Technical
- Relative Strength Index (RSI)
- KROS 20.25
- ATRO 58.88
- Support Level
- KROS $9.78
- ATRO $15.56
- Resistance Level
- KROS $16.49
- ATRO $17.10
- Average True Range (ATR)
- KROS 0.92
- ATRO 0.55
- MACD
- KROS 0.97
- ATRO 0.17
- Stochastic Oscillator
- KROS 14.52
- ATRO 88.62
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.